BTK and mantle cell lymphoma: Bruton’s Tyrosine Kinase (BTK) is a well-known target expressed in certain B-cell malignancies including mantle cell lymphoma and chronic lymphocytic leukemia, and several BTK inhibitors are approved for human use.